Literature DB >> 15662588

Frequent promoter methylation of tumor-related genes in sporadic and men2-associated pheochromocytomas.

R Dammann1, U Schagdarsurengin, C Seidel, C Trümpler, C Hoang-Vu, O Gimm, H Dralle, G P Pfeifer, M Brauckhoff.   

Abstract

Hypermethylation of CpG island promoters is associated with transcriptional inactivation of tumor suppressor genes in neoplasia. Inactivation of p16 and Pten was related to the development of pheochromocytomas. In this report, we investigated the methylation status of the p16INK4a cell cycle inhibitor gene and other prominent tumor-related genes ( PTEN, RASSF1 A, CDH1, MSH2, MLH1, VHL, and TIMP3) in sporadic and multiple endocrine neoplasia type 2 (MEN2) pheochromocytomas by methylation-specific PCR. Hypermethylation was detected in 48 % of pheochromocytomas for RASSF1 A, 24 % for p16, 36 % for MSH2, 16 % for CDH1, and 8 % for PTEN. No VHL, MLH1, and TIMP3 methylation was observed. Interestingly, the frequency of p16 inactivation in familial tumors was higher (5 out of 12, 42 %) than in sporadic tumors (1 out of 13, 8 %; p = 0.047) and RASSF1 A inactivation was more common in the hereditary tumors (58 %) compared to the sporadic tumors (38 %). Combined methylation of RASSF1 A and p16 was found only in MEN2-related pheochromocytomas. Thus, a subset of hereditary pheochromocytomas displays preferential methylation of p16 and RASSF1 A.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15662588     DOI: 10.1055/s-2004-830522

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  10 in total

1.  HNPCC-associated pheochromocytoma: expanding the tumor spectrum.

Authors:  Brian P Riff; Bryson W Katona; Myra Wilkerson; Katherine L Nathanson; David C Metz
Journal:  Pancreas       Date:  2015-05       Impact factor: 3.327

2.  Human pheochromocytomas show reduced p27Kip1 expression that is not associated with somatic gene mutations and rarely with deletions.

Authors:  Natalia S Pellegata; Leticia Quintanilla-Martinez; Gisela Keller; Sandya Liyanarachchi; Heinz Höfler; Michael J Atkinson; Falko Fend
Journal:  Virchows Arch       Date:  2007-06-07       Impact factor: 4.064

3.  Expression of the p16INK4A/Cdkn2a gene is prevalently downregulated in human pheochromocytoma tumor specimens.

Authors:  Peter Muscarella; Mark Bloomston; Alexander R Brewer; Anjali Mahajan; Wendy L Frankel; E Christopher Ellison; William B Farrar; Christopher M Weghorst; Junan Li
Journal:  Gene Expr       Date:  2008

Review 4.  Molecular markers of paragangliomas/pheochromocytomas.

Authors:  Svetlana O Zhikrivetskaya; Anastasiya V Snezhkina; Andrew R Zaretsky; Boris Y Alekseev; Anatoly V Pokrovsky; Alexander L Golovyuk; Nataliya V Melnikova; Oleg A Stepanov; Dmitry V Kalinin; Alexey A Moskalev; George S Krasnov; Alexey A Dmitriev; Anna V Kudryavtseva
Journal:  Oncotarget       Date:  2017-04-11

Review 5.  Impact of Natural Compounds on DNA Methylation Levels of the Tumor Suppressor Gene RASSF1A in Cancer.

Authors:  Reinhard H Dammann; Antje M Richter; Adriana P Jiménez; Michelle Woods; Miriam Küster; Chamindri Witharana
Journal:  Int J Mol Sci       Date:  2017-10-17       Impact factor: 5.923

6.  The VHL gene is epigenetically inactivated in pheochromocytomas and abdominal paragangliomas.

Authors:  Adam Andreasson; Nimrod B Kiss; Stefano Caramuta; Luqman Sulaiman; Fredrika Svahn; Martin Bäckdahl; Anders Höög; C Christofer Juhlin; Catharina Larsson
Journal:  Epigenetics       Date:  2013-10-22       Impact factor: 4.528

7.  Promoter methylation status of Ras-association domain family members in pheochromocytoma.

Authors:  Antje M Richter; Tobias Zimmermann; Tanja Haag; Sara K Walesch; Reinhard H Dammann
Journal:  Front Endocrinol (Lausanne)       Date:  2015-02-19       Impact factor: 5.555

8.  The dual specificity phosphatase 2 gene is hypermethylated in human cancer and regulated by epigenetic mechanisms.

Authors:  Tanja Haag; Antje M Richter; Martin B Schneider; Adriana P Jiménez; Reinhard H Dammann
Journal:  BMC Cancer       Date:  2016-02-01       Impact factor: 4.430

9.  ARHI is a novel epigenetic silenced tumor suppressor in sporadic pheochromocytoma.

Authors:  Dong Wang; Li Song; Liang Wang; Lianmei Zhao; Bai Xiang; Ying Li; Baoen Shan; Jing Liu
Journal:  Oncotarget       Date:  2017-09-21

Review 10.  Multiple Endocrine Neoplasia Syndromes from Genetic and Epigenetic Perspectives.

Authors:  Fatemeh Khatami; Seyed Mohammad Tavangar
Journal:  Biomark Insights       Date:  2018-07-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.